Takeda Pharmaceutical Company Launches Nutrition Initiative Addressing Climate Change Challenges in Indonesia
- Takeda Pharmaceutical Company funds the Climate-Inspired Nutrition Through Action program to improve maternal and child health in Indonesia.
- The initiative aims to train one million health workers in delivering climate-responsive nutrition solutions over five years.
- Takeda's collaboration with Vitamin Angels focuses on sustainable health interventions amidst climate challenges in Indonesia.
Takeda Pharmaceutical Company Backs Climate-Inspired Nutrition Initiative in Indonesia
In a significant move towards addressing maternal and child health challenges exacerbated by climate change, Takeda Pharmaceutical Company Limited funds the launch of the Climate-Inspired Nutrition Through Action (CINTA) program, executed by Vitamin Angels. Announced during a United Nations General Assembly side event in New York on September 23, 2025, this five-year initiative aims to enhance nutrition for vulnerable populations in Indonesia, particularly focusing on women and children. With over 30% of children under five suffering from stunting and nearly one-third of women of reproductive age experiencing anemia, the program addresses urgent nutritional needs while also promoting climate resilience in the healthcare sector.
The CINTA program aspires to train approximately one million health workers, equipping them with the knowledge and tools necessary to deliver climate-responsive nutrition solutions. The initiative comes at a critical time for Indonesia, which ranks 46 out of 163 on UNICEF's Children's Climate Risk Index, reflecting the severe threats posed by climate change to these vulnerable groups. Dr. Ana Céspedes, CEO of Vitamin Angels, underscores the importance of preventing health consequences for these populations due to the changing climate, stating that the program will build a robust framework for sustainable health interventions.
With an integrated approach, the CINTA program encompasses a range of nutrition interventions, including multiple micronutrient and vitamin A supplementation, deworming treatments, breastfeeding support, and nutrition education initiatives. A crucial component of the program involves strengthening supply chains to foster sustainable local production of essential nutrition supplies. Toshie Ando, Head of Global CSR & Partnership Strategy at Takeda, reinforces the company’s commitment to long-term investments in health solutions that are resilient to climate challenges. This collaboration not only aims to improve immediate health outcomes but also seeks to create lasting changes in maternal and child health across Indonesia.
In addition to enhancing nutrition, the CINTA program serves as a strategic response to the intertwined issues of climate change and public health. By leveraging Takeda's resources and expertise, Vitamin Angels plans to expand its reach and impact, ensuring that the most nutritionally vulnerable populations receive the necessary support. The initiative highlights the critical intersection of health and environmental sustainability, paving the way for healthier futures for generations to come.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

